Home › Plasma Cell Cancer
Pag-aaral pangklinika para sa Plasma Cell Cancer na nagre-recruit sa U.S.
24 pag-aaral para sa Plasma Cell Cancer ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX5 pag-aaral
- Boston, MA5 pag-aaral
- New York City, NY4 pag-aaral
- Atlanta, GA4 pag-aaral
- Miami, FL3 pag-aaral
- Durham, NC3 pag-aaral
Ayos sa estado
- California3 pag-aaral
- Florida4 pag-aaral
- Georgia4 pag-aaral
- Massachusetts5 pag-aaral
- New Jersey4 pag-aaral
- New York6 pag-aaral
- North Carolina4 pag-aaral
- Texas7 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Rutgers University Study of the Genetics of Blood Cancers
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07714044Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04879043Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 7 hanggang 80 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT00106925MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT06152575Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
Nagre-recruitPhase 1/2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06066359A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT05651932Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT07426484Delayed Toxicities Post-CAR-T
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT07665307Pre-malignant States to Hematologic Malignancies in Firefighters
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 49 · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT06870760Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT05055063High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06313502A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update May 26, 2026 · NCT07052916Pilot Imaging Study of Leukemia
Nagre-recruitPhase 1
Edad 4 hanggang 80 · Lahat ng kasarian · Na-update Abr 23, 2026 · NCT03633955Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT05336383Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 20, 2026 · NCT05745285Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Nagre-recruit
Edad 21 pataas · Lahat ng kasarian · Na-update Peb 5, 2026 · NCT07390071Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 11, 2025 · NCT06518551Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 3, 2025 · NCT06947083Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2025 · NCT07075510Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 27, 2025 · NCT01137643HEME Home Transfusion Program
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2025 · NCT06487247Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 10, 2025 · NCT05597345A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 2, 2024 · NCT06271252Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.